Addressing the Gaps in Malaria Treatment in Korea

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. kyungminhuh.id@gmail.com.

Editorial

Kyungmin Huh. J Korean Med Sci. 2024.

. 2024 Dec 23;39(49):e331.

doi: 10.3346/jkms.2024.39.e331.

¹ Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. kyungminhuh.id@gmail.com.

No abstract available

Conflict of interest statement

The author has no potential conflicts of interest to disclose.

Suboptimal Doses of Antimalarials Relative to Increasing Body Weight and the Risk of Plasmodium vivax Recurrence in the Republic of Korea Armed Forces, 2012–2021

1. Chai JY. History and current status of malaria in Korea. Infect Chemother. 2020;52(3):441–452. - PMC - PubMed
1. Kim H, Lee S, Shin NR, Hwang K. Status of malaria and diagnosis rate in the Republic of Korea, 2018-2022. Public Health Wkly Rep. 2023;16(26):852–866.
1. Hwang YH, Yoon D, Go S, Yeom JS, Oh HS. Suboptimal doses of antimalarials relative to increasing body weight and the risk of plasmodium vivax recurrence in the Republic of Korea Armed Forces, 2012–2021. J Korean Med Sci. 2024;39(49):e314 - PubMed
1. World Health Organization. WHO guidelines for malaria, 14 March 2023. [Updated 2023]. [Accessed November 2, 2024]. https://iris.who.int/handle/10665/366432 .
1. Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24(2):172–183. - PMC - PubMed